-
Something wrong with this record ?
Pros and Cons of Portal Vein Embolization With Hematopoietic Stem Cells Application in Colorectal Liver Metastases Surgery
V. Treska, J. Bruha, V. Liska, J. Fichtl, K. Prochazkova, T. Petrakova, P. Hosek
Language English Country Greece
Document type Journal Article
NLK
Free Medical Journals
from 2004 to 2 years ago
PubMed Central
from 2017
Europe PubMed Central
from 2017
Open Access Digital Library
from 2004-01-01
PubMed
32871833
DOI
10.21873/invivo.12121
Knihovny.cz E-resources
- MeSH
- Hematopoietic Stem Cells MeSH
- Hepatectomy adverse effects MeSH
- Colorectal Neoplasms * MeSH
- Humans MeSH
- Liver Neoplasms * surgery MeSH
- Preoperative Care MeSH
- Embolization, Therapeutic * adverse effects MeSH
- Portal Vein surgery MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND/AIM: Portal vein embolization (PVE) with autologous stem cells application (aHSC) is a method for future liver remnant volume (FLRV) increase. The aim of the study was to evaluate the positivite and negativite aspects of the method in clinical practice. PATIENTS AND METHODS: PVE with aHSC application was used in 32 patients with colorectal liver metastases and insufficient FLRV. Preoperative number of colorectal liver metastases (CLMs) was 5.2±3.6, CLMs volume 70.1±102.3 mm3 Results: FLRV growth occurred after 2-3 weeks in 31 (96.9%) patients, with volume increase from 528.2±170.5 to 715.4±143.3 ml (p=0.0001). Postoperative thirty days mortality, morbidity was 0% and 3.1%, respectively. Insufficient FLRV growth occurred in one patient. R0 liver resection was performed in 27(87.1%) patients. CLMs volume progression was in 5 (15.6%) patients from 680.0±59.4 to 723.1±57.1 ml (p=0.01). One and two-year overall survival were 88% and 62.9% respectively. Six and twelve-month recurrence-free survival rates were 50.7% and 39.6% respectively. CONCLUSION: PVE with aHSC application is a safe and useful method for FLRV growth. It significantly increases secondary CLMs resectability. However, it can cause CLMs progression. Liver resection should, therefore, be performed as soon as possible after achieving optimal increase of FLRV.
Biomedical Centre School of Medicine Pilsen Czech Republic
Department of Surgery School of Medicine University Hospital in Pilsen Pilsen Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020185
- 003
- CZ-PrNML
- 005
- 20210830101818.0
- 007
- ta
- 008
- 210728s2020 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/invivo.12121 $2 doi
- 035 __
- $a (PubMed)32871833
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Treska, Vladislav $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic treska@fnplzen.cz
- 245 10
- $a Pros and Cons of Portal Vein Embolization With Hematopoietic Stem Cells Application in Colorectal Liver Metastases Surgery / $c V. Treska, J. Bruha, V. Liska, J. Fichtl, K. Prochazkova, T. Petrakova, P. Hosek
- 520 9_
- $a BACKGROUND/AIM: Portal vein embolization (PVE) with autologous stem cells application (aHSC) is a method for future liver remnant volume (FLRV) increase. The aim of the study was to evaluate the positivite and negativite aspects of the method in clinical practice. PATIENTS AND METHODS: PVE with aHSC application was used in 32 patients with colorectal liver metastases and insufficient FLRV. Preoperative number of colorectal liver metastases (CLMs) was 5.2±3.6, CLMs volume 70.1±102.3 mm3 Results: FLRV growth occurred after 2-3 weeks in 31 (96.9%) patients, with volume increase from 528.2±170.5 to 715.4±143.3 ml (p=0.0001). Postoperative thirty days mortality, morbidity was 0% and 3.1%, respectively. Insufficient FLRV growth occurred in one patient. R0 liver resection was performed in 27(87.1%) patients. CLMs volume progression was in 5 (15.6%) patients from 680.0±59.4 to 723.1±57.1 ml (p=0.01). One and two-year overall survival were 88% and 62.9% respectively. Six and twelve-month recurrence-free survival rates were 50.7% and 39.6% respectively. CONCLUSION: PVE with aHSC application is a safe and useful method for FLRV growth. It significantly increases secondary CLMs resectability. However, it can cause CLMs progression. Liver resection should, therefore, be performed as soon as possible after achieving optimal increase of FLRV.
- 650 12
- $a kolorektální nádory $7 D015179
- 650 12
- $a terapeutická embolizace $x škodlivé účinky $7 D004621
- 650 _2
- $a hematopoetické kmenové buňky $7 D006412
- 650 _2
- $a hepatektomie $x škodlivé účinky $7 D006498
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory jater $x chirurgie $7 D008113
- 650 _2
- $a vena portae $x chirurgie $7 D011169
- 650 _2
- $a předoperační péče $7 D011300
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bruha, Jan $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Liska, Vaclav $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Fichtl, Jakub $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Prochazkova, Kristyna $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Petrakova, Tereza $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Hosek, Petr $u Biomedical Centre, School of Medicine, Pilsen, Czech Republic
- 773 0_
- $w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 34, č. 5 (2020), s. 2919-2925
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32871833 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101819 $b ABA008
- 999 __
- $a ok $b bmc $g 1690888 $s 1140631
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 34 $c 5 $d 2919-2925 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
- LZP __
- $a Pubmed-20210728